UTHR
United Therapeutics CorporationNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 29, 3:28 PM
    • Barclays' Geoff Meacham has downgraded BioMarin Pharmaceutical (BMRN -1.4%), Johnson & Johnson (JNJ -0.5%), Seattle Genetics (SGEN -0.2%), United Therapeutics (UTHR -4.1%) and Vertex Pharmaceuticals (VRTX -0.9%) to Equal Weight from Overweight.
    • He trimmed BMRN's price target to $105 (21% upside) from $125 citing "moderating growth and an overall lack of catalysts in 2017."
    • J&J's price target was sliced to $125 (11% upside) from $130 due to a "less compelling risk/reward profile."
    • SGEN's fair value target was lowered to $53 (21% downside risk) from $70 due to valuation.
    • UTHR's price target was revised to $100 (21% downside risk) from $115 citing the likely impact of Uptravi on Orenitram uptake.
    • He lowered Vertex's price target to $90 (5% upside) from $100 citing the lack of upside for Kalydeco and Orkambi.
    | Tue, Nov. 29, 3:28 PM | 13 Comments
  • Fri, Oct. 28, 1:02 PM
    • United Therapeutics (NASDAQ:UTHR) upgraded to Buy from Neutral by Ladenburg Thalmann. Price target raised to $138 (18% upside) from $128.
    • NeoGenomics (NASDAQ:NEO) upgraded to Buy from Neutral with a $10 (25% upside) price target by BTIG Research.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) upgraded to Market Perform from Underperform by BMO Capital. Price target raised to $36 (8% upside) from $35.
    • Alkermes (NASDAQ:ALKS) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $78 (53% upside) from $51.
    • McKesson (NYSE:MCK) downgraded to Neutral from Outperform by Baird. Price target lowered to $164 (34% upside) from $200. Also downgraded by Standpoint Research, Deutsche Bank and Leerink Swann.
    • Community Health Systems (NYSE:CYH) downgraded to Underperform from Neutral by Baird. Price target lowered to $8 (47% upside) from $12.
    • TeamHealth Holdings (NYSE:TMH) downgraded to Market Perform from Outperform by Leerink Swann. Price target raised to $43 (17% upside) from $40..
    • ARIAD Pharmaceuticals (NASDAQ:ARIA) downgraded to Market Perform from Market Outperform by JMP Securities. Price target raised to $9.37 (7% upside) from $4.37.
    • Vertex Pharmaceuticals (NASDAQ:VRTX) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $85 (8% upside) from $155.
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) downgraded to Neutral from Buy by Mizuho. Price target lowered to $45 (7% upside) from $64.
    | Fri, Oct. 28, 1:02 PM | 5 Comments
  • Thu, Oct. 27, 7:05 AM
    • United Therapeutics (NASDAQ:UTHR) Q3 results ($M): Total Revenues: 408.2 (+5.7%).
    • Net Income: 161.8 (-65.2%); Non-GAAP Net Income: 201.5 (+15.3%); EPS: 3.50 (-62.1%); Non-GAAP EPS: 4.36 (+25.3%).
    • Key Product Sales: Remodulin: 152.4 (+1.5%); Tyvaso: 101.8 (-16.4%); Adcirca: 96.0 (+30.1%); Orenitram: 40.7 (18.3%); Unituxin: 17.3 (+268.1%).
    • No guidance given.
    • Consensus view was EPS of $3.34 on revenues of $402.4M.
    | Thu, Oct. 27, 7:05 AM | 2 Comments
  • Thu, Oct. 27, 6:02 AM
    • United Therapeutics (NASDAQ:UTHR): Q3 EPS of $4.36 beats by $1.02.
    • Revenue of $408.2M (+5.7% Y/Y) beats by $5.85M.
    • Press Release
    | Thu, Oct. 27, 6:02 AM | 4 Comments
  • Wed, Oct. 26, 5:30 PM
  • Thu, Jul. 28, 7:51 AM
    • United Therapeutics (NASDAQ:UTHR) Q2 results ($M): Total Revenues: 412.6 (+19.3%).
    • Key Product Sales: Remodulin: 158.9 (+16.9%); Tyvaso: 107.0 (-7.6%); Adcirca: 90.9 (+33.3%); Orenitram: 38.0 (+46.7%); Unituxin: 17.8.
    • Net Income: 206.1 (+107.8%); Non-GAAP Net Income: 213.3 (+60.6%); EPS: 4.39 (+129.8%); Non-GAAP EPS: 4.55 (+77.7%).
    • Shares are up 2% premarket on light volume.
    | Thu, Jul. 28, 7:51 AM | 2 Comments
  • Thu, Jul. 28, 6:04 AM
    • United Therapeutics (NASDAQ:UTHR): Q2 EPS of $4.55 beats by $1.33.
    • Revenue of $412.6M (+18.9% Y/Y) beats by $17.45M.
    • Press Release
    | Thu, Jul. 28, 6:04 AM | 4 Comments
  • Wed, Jul. 27, 5:30 PM
  • Fri, Jun. 17, 7:06 AM
    • Hill Rom Holdings (NYSE:HRC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $62 (20% upside) from $54.
    • Arbutus Biopharma (NASDAQ:ABUS) upgraded to Neutral from Sell by Chardan. Price target is $3.25 (1% downside risk).
    • Achaogen (NASDAQ:AKAO) upgraded to Outperform from Neutral by Wedbush. Price target raised to $10 (111% upside) from $7.
    • PRA Health Sciences (NASDAQ:PRAH) upgraded to Overweight from Sector Weight by KeyBanc. Price target is $55 (25% upside).
    • Agios Pharmaceuticals (NASDAQ:AGIO) upgraded to Buy from Hold by JPMorgan. Price target raised to $62 (30% upside) from $50.
    • Quidel (NASDAQ:QDEL) upgraded to Outperform from Market Perform by Raymond James. Price target is $21.50 (20% upside).
    • Aptose Biosciences (NASDAQ:APTO) upgraded to Buy from Neutral by Roth Capital. Price target raised to $8 (186% upside) from $4.
    • Endologix (NASDAQ:ELGX) upgraded to Buy from Hold with a $15.50 (23% upside) price target by Canaccord Genuity.
    • Endo International (NASDAQ:ENDP) upgraded to Neutral from Underperform by Mizuho Securities. Price target raised to $16 (5% downside risk) from $13.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $95 (11% downside risk) from $175.
    • Infinity Pharmaceuticals (NASDAQ:INFI) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $1 (32% downside risk) from $11.
    • LDR Holding (NASDAQ:LDRH) downgraded to Market Perform from Outperform by Cowen & Company.
    • Marinus Pharmaceuticals (NASDAQ:MRNS) downgraded to Perform from Outperform by Oppenheimer. $17 price target removed. Also downgraded to Sector Perform from Outperform by RBC Capital.
    • Mesoblast (NASDAQ:MESO) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $5 (21% upside) from $10.
    • Revance Therapeutics (NASDAQ:RVNC) downgraded to Hold from Buy by Brean Capital. Price target removed.
    • OraSure (NASDAQ:OSUR) downgraded to Market Perform from Outperform by Raymond James. Price target is $8 (15% upside).
    | Fri, Jun. 17, 7:06 AM | 3 Comments
  • Fri, May 27, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    | Fri, May 27, 4:56 PM | 17 Comments
  • Thu, Apr. 28, 11:29 AM
    • United Therapeutics (UTHR -9.3%) Q1 results: Revenues: $369M (+12.7%); R&D Expense: $0.4M (-99.6%); SG&A: $5M (-97.6%); Operating Income: $363.7M (+999%); Net Income: $235.5M (+999%); EPS: $4.84 (+999%); Non-GAAP EPS: $3.02 (+18.4%); Quick Assets: $985.5.
    • No guidance given.
    | Thu, Apr. 28, 11:29 AM
  • Thu, Apr. 28, 6:04 AM
    • United Therapeutics (NASDAQ:UTHR): Q1 EPS of $3.02 misses by $0.03.
    • Revenue of $369M (+12.7% Y/Y) misses by $28.42M.
    | Thu, Apr. 28, 6:04 AM | 2 Comments
  • Wed, Apr. 27, 5:30 PM
  • Mon, Apr. 11, 5:43 PM
    • SteadyMed (NASDAQ:STDY) is apparently in good spirits upon hearing that the U.S. Patent and Trademark Office has initiated an inter partes review of a patent (U.S. Patent No. 8,497,393 or the '393 patent) owned by United Therapeutics (NASDAQ:UTHR) covering the process to further purify prostacyclin derivatives such as treprostinil, the active pharmaceutical ingredient in Remodulin. Treprostinil is also the active ingredient in SteadyMed's lead candidate, Trevyent. Both treat pulmonary arterial hypertension.
    • An inter partes review is procedure for challenging the validity of a U.S. patent.
    • SteadyMed is keenly interested in a ruling that the '393 patent is invalid considering it intends to file its New Drug Application (NDA) seeking approval of Trevyent later this year. According to the company, it has reason to be optimistic. From 2012-2015, only 12% of cases decided by final decision after institution resulted in all claims patentable, while 74% found all claims unpatentable and 14% found some claims unpatentable.
    • The company will host a reception for analysts and investors in New York on April 20 during which management will present a corporate update and overview of Trevyent.
    | Mon, Apr. 11, 5:43 PM | 4 Comments
  • Thu, Feb. 25, 11:20 AM
    • United Therapeutics (UTHR -5.6%) Q4 results: Revenues: $404.9M (+16.9%); R&D Expense: $75.9M (+6.2%); SG&A: $148.6M (+84.6%); Operating Income: $155.1M (-13.2%); Net Income: $104.6M (-9.7%); EPS: $2.10 (-3.2%); Non-GAAP EPS: $3.68 (+30.0%).
    • FY2015 results: Revenues: $1465.8M (+13.8%); R&D Expense: $245.1M (+1.1%); SG&A: $452.6M (+18.7%); Operating Income: $699M (+29.7%); Net Income: $651.6M (+91.6%); EPS: $12.72 (+102.5%); Non-GAAP EPS: $12.33 (+33.2%); Quick Assets: $991.8M (+21.2%).
    • No guidance given.
    | Thu, Feb. 25, 11:20 AM
  • Thu, Feb. 25, 6:03 AM
    • United Therapeutics (NASDAQ:UTHR): Q4 EPS of $3.68 beats by $1.13.
    • Revenue of $404.88M (+16.9% Y/Y) beats by $16.59M.
    | Thu, Feb. 25, 6:03 AM